Galenicum Axium's headquarters are based in Barcelona. And from there, we reach the world!
We currently supply our pharmaceutical products to over 150 pharmaceutical companies in 50 countries around the world, and our growth plans makes us more global than ever. In our current projections, we will reach 20 new countries by 2025, specially increasing our presence in ROW countries. Our core markets will continue to be the regulated markets, specially Europe.
The information contained in this section is aimed at the healthcare professional of the Pharmaceutical Industry, therefore, specialized training is required for its correct interpretation.
The products mentioned may have a different authorized data sheet in each country.
If you click the "accept" button, you are expressing your willingness to access the information explicitly intended for healthcare professionals.
DEVELOPMENT OF THE FIRST GENERIC PHARMACEUTICAL SPECIALTY WITH DABIGATRAN. Decision EMC/2755/2017, dated November 20, (DOGC núm. 7508 of 30/11/2017) regarding the call for NUCLEUS OF INDUSTRIAL RESEARCH AND EXPERIMENTAL DEVELOPMENT (file number RD17-1-0006). This project has received funding from the European Union through the European Regional Development Fund (ERDF). With the collaboration from ACCIÓ.